Skip to main content
HLB bioStep Co.,Ltd. logo

HLB bioStep Co.,Ltd. — Investor Relations & Filings

Ticker · 278650 ISIN · KR7278650007 KO Professional, scientific and technical activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2023-07-13 Capital/Financing Update
Country KR South Korea
Listing KO 278650

About HLB bioStep Co.,Ltd.

http://hlbbiostep.com/en/

HLB bioStep Co.,Ltd. is a non-clinical Contract Research Organization (CRO) that provides a range of testing services to pharmaceutical companies and bio ventures. The company's core services support new drug development and include efficacy testing, pharmacokinetic/toxicokinetic (PK/TK) studies, and toxicology evaluations. A key area of specialization is veterinary medicine; HLB bioStep is an institution approved to conduct non-clinical tests and clinical trials for veterinary drugs. It also offers consulting services for regulatory approval procedures. The company utilizes various platform technologies, such as cell-enzyme-based screening and xenograft assays, and provides a comprehensive 'One-Stop Service' that leverages its experience in building laboratory facilities.

Recent filings

Filing Released Lang Actions
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from HLB Life Science (HLB바이오스텝) regarding the adjustment of the conversion price for convertible bonds (CB). This type of disclosure, which details changes to financial instruments and capital structure, falls under the category of 'Capital/Financing Update' (CAP) as it relates to the company's financing activities and debt instruments.
2023-07-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is required when an entity or individual crosses a significant ownership threshold in a publicly traded company. In the provided taxonomy, this corresponds to a 'Major Shareholding Notification'.
2023-07-11 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the change in shareholding percentage (from 5.17% to 6.18%) by Korea Securities Finance Corp in HLB BioStep. This type of filing is specifically categorized as a Major Shareholding Notification (MRQ) in the provided schema.
2023-07-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is the standard Korean regulatory filing for disclosing significant changes in share ownership (often referred to as the 5% rule filing). It details the reporter (HLB Co., Ltd.), special related parties, the purpose of holding (influence on management), and specific changes in shareholdings due to corporate actions like bonus issues and call option exercises. This fits the definition of a Major Shareholding Notification.
2023-06-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements of a major shareholder (Kim Do-hyung) in HLB Biostep. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-06-28 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a formal regulatory filing titled '타법인주식및출자증권취득결정' (Decision to acquire shares and equity securities of another corporation). It details the acquisition of shares in Panagene by HLB BioStep, including the number of shares, acquisition amount, purpose, and financial status of the target company. This type of corporate disclosure regarding M&A or strategic investment activity is classified as M&A Activity (TAR).
2023-06-21 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.